Welcome to our dedicated page for Iridex news (Ticker: IRIX), a resource for investors and traders seeking the latest updates and insights on Iridex stock.
Iridex Corporation develops, manufactures, and markets laser-based medical systems, delivery devices, procedure probes, accessories, and consumable instrumentation for ophthalmology. Its products support treatment of glaucoma, diabetic macular edema, and other retinal diseases, with proprietary MicroPulse® technology used across parts of its portfolio.
Iridex news commonly covers quarterly and annual financial results, business updates, product-family activity for systems such as Cyclo G6®, retina laser platforms including PASCAL®, IQ 532®, IQ 577®, and OcuLight® TX, and clinical literature involving MicroPulse transscleral laser therapy. Company updates also address commercial partnerships, U.S. direct sales, international distributor activity, operational efficiency measures, and Nasdaq listing-status matters.
IRIDEX (Nasdaq: IRIX), a leader in laser-based medical systems for glaucoma and retinal diseases, has announced a private placement financing with Lind Global Asset Management IX The deal involves a senior convertible promissory note that will provide net proceeds of approximately $3.5 million at closing, with potential for an additional $1.5 million through a subsequent note.
Key points:
- Initial note has a principal amount of $4,200,000
- 24-month term for each note
- Convertible into common stock at $2.44 per share
- Company can repay with reduced principal within 180 or 365 days
- Monthly repayments start after 120 days, with options for cash, stock, or combination
CEO David Bruce states this financing provides balance sheet liquidity and operating runway as they pursue their strategic process and growth recovery.
Iridex (NASDAQ: IRIX), a leader in laser-based medical systems for glaucoma and retinal diseases, has announced its plan to release second quarter 2024 financial results on August 8, 2024, after market close. The company will also provide a business update during a conference call scheduled for the same day at 2:00 p.m. PT / 5:00 p.m. ET.
Investors can join the call by dialing (646) 307-1963 (domestic) or (800) 715-9871 (international) using conference ID: 9156340. A live and recorded webcast will be available on the company's website at www.iridex.com under the 'Investors' section's 'Event Calendar' page.
Iridex (Nasdaq: IRIX) reported first-quarter 2024 financial results, showing a decline in revenue to $11.8 million from $13.7 million in Q1 2023. The Cyclo G6 product family revenue fell to $3.0 million from $3.7 million, despite selling more probes. Revenue from retina products decreased by 6% to $6.8 million. Cash and cash equivalents dropped to $5.4 million, a reduction of $1.6 million. The gross margin narrowed to 37.9% from 43.3%, and net loss widened to $3.5 million, or $0.21 per share, from $2.1 million, or $0.13 per share. CEO David Bruce noted longer sales cycles and end-of-quarter purchase deferrals but remains optimistic for the second quarter.
Iridex (NASDAQ: IRIX) will report its financial results for the first quarter of 2024 on May 14, 2024. The company specializes in laser-based medical systems for glaucoma and retinal diseases, with a conference call scheduled after the market closes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.